Company profile
ZEVRA THERAPEUTICS, INC.
NASDAQ:ZVRABiotechnology: Pharmaceutical Preparations
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Acetaminophen | approved | — | 78 | approved |
| ARIMOCLOMOL CITRATE | approved | — | 0 | — |
| BENZHYDROCODONE HYDROCHLORIDE | approved | — | 0 | — |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02612129 | phase2_3 | completed | 2016-06-14 | 2018-06-25 | ZevraDenmark | Arimoclomol Prospective Study in Participants Diagnosed With Niemann-Pick Disease Type C |
| NCT03491462 | phase3 | completed | 2018-07-31 | 2020-12-18 | ZevraDenmark | Arimoclomol in Amyotropic Lateral Sclerosis |
| NCT03836716 | phase3 | terminated | 2019-09-19 | 2021-07-02 | ZevraDenmark | Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial |
| NCT04049097 | phase3 | terminated | 2019-05-20 | 2021-11-15 | ZevraDenmark | Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial |
| NCT03292952 | phase3 | completed | 2017-12-20 | 2018-05-16 | Zevra Therapeutics | KP415 Classroom Study in Children (6-12 Years of Age) With ADHD |
FDA applications (2)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 208653 | NDA | ZEVRA THERAPEUTICS | ||||
Loading… | ||||||
| NDA 214927 | NDA | ZEVRA DENMARK AS | ||||
Loading… | ||||||